Advertisement

Reactions Weekly

, Volume 1736, Issue 1, pp 108–108 | Cite as

Gemcitabine/oxaliplatin/paclitaxel

Neutropenia: 2 case reports
Case report
  • 36 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series an adult woman experienced neutropenia during treatment with gemcitabine, oxaliplatin and paclitaxel for metastatic choriocarcinoma, and an adult woman experienced neutropenia during treatment with gemcitabine, oxaliplatin and paclitaxel for metastatic gestational trophoblastic neoplasia [exact ages at the time of reactions onset not stated; time to reactions onset not stated].

Patient 1: The woman presented to a hospital in China in October 2016 at the age of 29 years, with a suspicion of choriocarcinoma. Her β-human chorionic gonadotropin (β-hCG) level was 4,408 mIU/mL. The International Federation of Gynecology and Obstetrics (FIGO) score of 13 indicated an extremely high risk choriocarcinoma. Upon CT and ultrasound examinations, she was found to have...

Reference

  1. Huang Y, et al. Salvage therapy of extremely high-risk and resistant gestational trophoblastic neoplasia with gemcitabine, oxaliplatin, and paclitaxel: A report of 3 cases. Journal of Reproductive Medicine 63: 530-534, No. 6, Dec 2018 - ChinaGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations